Table 2. Hazard ratio and 95% confidence interval for the composite outcome, effectiveness outcome, and safety outcome, in the early OAC use group and in the delayed OAC use group ^a .

Stroke severity	Mild		Moderate		Severe
OAC use	Early vs. no use	Delayed vs. no use	Early vs. no use	Delayed vs. no use	Early vs. no use	Delayed vs. no use
Composite outcome
	0·75 (0·65, 0·87)	0·73 (0·62, 0·85)	0·73 (0·61, 0·88)	0·82 (0·67, 1·00)	0·79 (0·68, 0·92)	0·89 (0·73, 1·08)
Stratified by:
NOAC	0·64 (0·47, 0·85)	0·61 (0·49, 0·76)	0·59 (0·38, 0·93)	0·73 (0·55, 0·97)	0·77 (0·51, 1·17)	1·10 (0·84, 1·45)
Warfarin	0·89 (0·74, 1·06)	0·88 (0·68, 1·14)	0·79 (0·63, 1·00)	0·76 (0·55, 1·06)	0·86 (0·72, 1·03)	0·61 (0·45, 0·82)
Effectiveness outcome
	0·83 (0·70, 0·98)	0·69 (0·58, 0·83)	0·88 (0·72, 1·07)	0·84 (0·68, 1·03)	0·82 (0·70, 0·95)	0·76 (0·63, 0·92)
Stratified by:
NOAC	0·78 (0·56, 1·07)	0·52 (0·40, 0·68)	0·93 (0·59, 1·46)	0·82 (0·63, 1·08)	0·58 (0·39, 0·86)	1·02 (0·78, 1·32)
Warfarin	0·86 (0·69, 1·06)	0·99 (0·75, 1·30)	0·95 (0·75, 1·20)	0·80 (0·56, 1·14)	0·98 (0·82, 1·18)	0·52 (0·39, 0·71)
Safety outcome
	0·96 (0·76, 1·22)	0·75 (0·61, 0·93)	1·08 (0·80, 1·46)	0·94 (0·69, 1·28)	1·67 (1·30, 2·13)	1·16 (0·88, 1·53)
Stratified by:
NOAC	1·00 (0·58, 1·71)	0·77 (0·58, 1·03)	1·13 (0·61, 2·10)	0·81 (0·51, 1·28)	2·10 (1·13, 3·92)	1·18 (0·78, 1·78)
Warfarin	0·95 (0·71, 1·28)	0·73 (0·52, 1·02)	1·07 (0·73, 1·57)	1·11 (0·68, 1·80)	1·76 (1·29, 2·39)	1·05 (0·69, 1·59)

Abbreviations: AF, atrial fibrillation; NOAC, non-vitamin K antagonist oral anticoagulant; OACs, oral anticoagulants.

Note: Statistically significant values are denoted in bold.

^aA sequence of PS-matched cohorts for each of the three outcomes was constructed on each day from the first to the 30th day of admission. Data of PS-matched cohorts were pooled together for analyses.